Glycobiology is the branch of science which deals with the study of Glycan and glycan-modified biomolecules such as glycolipids, glycoproteins and glycosylated small molecules collectively referred to as sugar molecules. Glycan are universal in all aspects of life. The binding of carbohydrate structures to biomolecules, including lipids, proteins, metabolites, and nucleic acids, can profoundly affect their physicochemical properties, subcellular localization, immunogenicity, and pharmacokinetics and pharmacodynamics.
All cells and many proteins such as glycoproteins are covered with dense and complex arrays of covalently linked sugar chains (called oligosaccharides or glycan). The biological roles of these glycan are of particular importance in the assembly of complex multicellular organs and organisms, processes that require interactions between cells and with the surrounding extracellular matrix. Most classes of glycan are found on the surface of cells and secreted macromolecules. In addition, simple, rapidly metabolizing protein-bound glycan are abundant in the nucleus and cytoplasm, where they function as regulatory switches.
Glycan are diverse and complex molecules whose functions are determined by their unique structures. Glycan structures requires effective enzymatic tools and analytical techniques and can be associated with specific functions. Glycosylation defines the adhesive properties of proteins and cells. The immune system functions primarily through carbohydrate-protein interactions, highlighting the importance of carbohydrates in physiology, pathogen recognition, cancer, and autoimmune diseases.
Market Dynamics
Major factors driving growth of the glycobiology market include adoption of inorganic growth strategies such as acquisitions by key players in the market. For instance, in June, 2018, Agilent Technologies, an American life science company, has acquired privately held ProZyme Inc., a provider of glycan analysis, reagents and kits. This acquisition will help the company expand its glycobiology product portfolio
Key features of the study
- This report provides in-depth analysis of the global glycobiology market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global glycobiology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Tracxn Technologies Limited, Agilent Tecnologies,Inc., Blirt.eu, Takara Bio Inc., Bio-Techne, Bruker Corporation, Thermo Fisher Scientific Inc., Shimadzu Corporation, New England Biolabs., Waters.co., Merck KGaA, Palleon Pharmaceuticals, Asparia Glycomics, RayBiotech Life, Inc., Z Biotech, LLC., Chemily Glycoscience, Lectenz Bio, 2BScientific , and Glycodiag
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global glycobiology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycobiology market
Market Segmentation
- Product Type Insights (Revenue, USD Bn, 2026 - 2033)
- Instruments
- Enzymes
- Glycosidase
- Heparinase
- Chitinase
- Acetylgalactosaminidase
- PNGase
- Chitobiase
- Others (Hyaluronidase , Hexosaminidase)
- GlcNAc Transferases
- Acetylglucosaminyltransferase
- Exostosin
- Others (GD2 Synthase,B3GANLT)
- GalNAc Transferases
- Polypeptide GalNAc Transferase
- GANLTL
- Others
- Fucosyl Transferases
- Galactosyl Transferases
- Carbohydrate Kinases
- Others
- Consumables
- Reagents & Kits
- Application Insights (Revenue, USD Bn, 2026 - 2033)
- Diagnostic Application
- Industrial Application
- Therapeutic Application
- Drug Discovery and Development
- Others
- End User Insights (Revenue, USD Bn, 2026 - 2033)
- Research Laboratories
- Hospitals
- Diagnostic Centres
- Biopharmaceutical Companies
- Others
- Food
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Tracxn Technologies Limited
- Agilent Tecnologies, Inc
- Blirt.eu
- Takara Bio Inc.
- Bio-Techne
- Bruker Corporation
- Thermo Fisher Scientific Inc
- Shimadzu Corporation
- New England Biolabs.
- Waters.co.
- Merck KGaA
- Palleon Pharmaceuticals
- Asparia Glycomics
- RayBiotech Life, Inc
- Z Biotech, LLC
- Chemily Glycoscience
- Lectenz Bio,
- 2BScientific
- Glycodiag
